Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study

PURPOSE: Pyrotinib, a novel human epidermal growth factor receptor 2 (HER2)-targeted tyrosine kinase inhibitor (TKI), has led to remarkable survival outcomes in HER2-positive advanced breast cancer (ABC) in clinical trials and was approved for second-line standards of treatment for HER2+ ABC in Chin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoling, Li, Zhaohui, Han, Linlin, Lv, Zheng, Teng, Yuee, Cui, Xiujie, Zhou, Caiyun, Wu, Hongwei, Fang, Wei, Xu, Lingzhi, Zhao, Shanshan, Song, Chen, Zheng, Yuanyuan, Gao, Tianqi, Li, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527812/
https://www.ncbi.nlm.nih.gov/pubmed/36199295
http://dx.doi.org/10.2147/OTT.S379591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527812/
https://www.ncbi.nlm.nih.gov/pubmed/36199295
http://dx.doi.org/10.2147/OTT.S379591

Ejemplares similares